HDAC9 and breast carcinoma: In breast cancer cells, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), which is a potent and reversible HDAC inhibitor (HDACi), inhibited ERα expression and transcriptional activity [44,45] via the disturbance of HDAC activity.